Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant
Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Vivani’s NanoPortal platform for chronic weight management. Vivani has initiated a Phase 1 clinical study of the implant, while Novo Nordisk assesses semaglutide in this drug delivery format. The partnership focuses on an implantable GLP-1 approach that could offer an alternative to pills and injections for obesity treatment. Novo Nordisk, traded as CPSE:NOVO B, is already a central player in...
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.